Peptide education
Gallium Ga-68 dotatate
Ga-68 DOTATATE · 68Ga-DOTATATE · NETSPOT
Gallium Ga-68 dotatate is a radioactive medicine used with a PET scan to locate neuroendocrine tumors that have somatostatin receptors. NETSPOT is a US-approved kit used to prepare this imaging agent.
PET can show where the tracer accumulates, but receptor uptake is not specific to neuroendocrine tumors. A negative scan can miss tumors that do not express enough receptor, and results need clinical interpretation.
Overview
Quick answer
This is a diagnostic scan, not a cancer treatment. Lutetium Lu-177 dotatate is a different radioactive medicine that also targets somatostatin receptors but is used for treatment in a defined group of patients.
What is NETSPOT approved to do?
After radiolabeling, it is used with PET to locate somatostatin receptor-positive neuroendocrine tumors in adults and children.
How is the scan prepared?
The labeled activity is 2 MBq/kg, equivalent to 0.054 mCi/kg, up to 200 MBq or 5.4 mCi, given by intravenous bolus. The label describes image acquisition 40 to 90 minutes after injection.
Does uptake prove a tumor is cancer?
No. Other tumors, certain noncancerous conditions and normal tissue can show uptake. Tumors without the receptor may not be visible.
Is this the same as Lu-177 dotatate?
No. This gallium-68 preparation is an imaging agent. The similarly named lutetium-177 product is a therapeutic radiopharmaceutical.
Evidence
Evidence snapshot
The US label covers receptor-positive neuroendocrine tumors in adult and pediatric patients.
In a study of 97 enrolled patients, 78 had comparable gallium-68 dotatate and indium-111 pentetreotide scans. Gallium-68 PET/CT combined with CT or liver MRI changed care in 28 of these 78 patients.
The study was not a randomized test of whether imaging improves survival.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| A positive DOTATATE PET scan always means neuroendocrine cancer. | In a study summarized in the label, seven of 68 patients without a NET identified by the reference standard had a false-positive scan. | A positive signal alone does not establish the diagnosis. Other tumors, normal structures and some other conditions may also accumulate the tracer. | |
| A negative scan rules out every neuroendocrine tumor. | In the same study, seven of 36 patients with a NET identified by the reference standard had a false-negative scan. | The label states that tumors without somatostatin receptors will not be visualized. | No. Imaging results depend on receptor expression and interpretation. |
| The scan treats the tumors it finds. | In a prospective study, DOTATATE PET/CT was used to evaluate patients with known or suspected neuroendocrine tumors. It was not tested as a treatment. | No. Gallium-68 dotatate imaging and Lu-177 dotatate treatment are distinct. |
Bottom line
Main takeaway
This tracer helps a PET scanner locate receptor-bearing tissue; it is not a treatment.
Both false-positive and false-negative interpretations are possible.
The 28 of 78 management result applies to the comparison subset, not a randomized survival endpoint.
Identity
What it is
Use context
Routes, doses, and cycle patterns
NETSPOT activity is measured in MBq or mCi, not peptide mass. The US label specifies a weight-based amount and a maximum activity.
Human studies and product labels
NETSPOT imaging activity
- Purpose
- PET localization of receptor-positive neuroendocrine tumors
- Context
- US prescribing information
- Route
- Intravenous bolus by qualified personnel
- Amount
- 2 MBq/kg (0.054 mCi/kg), up to 200 MBq (5.4 mCi)
- Frequency
- One injection for the imaging procedure
- Duration
- PET acquisition 40 to 90 minutes after injection
The activity is measured at administration. Timing and interpretation belong to the imaging team, and the scan is not a treatment regimen.
What varies
- The label advises hydration before the scan and frequent urination in the first hours afterward to reduce radiation exposure.
- Somatostatin analogs can affect imaging. The label places the scan just before the next long-acting analog dose and permits short-acting analogs up to 24 hours before imaging. Medication timing requires the clinical team.
- Repeated high-dose glucocorticoids before imaging may result in a false-negative scan.
Research
Research evidence
A prospective imaging study enrolled 97 people with known or suspected neuroendocrine tumors. A subset of 78 had comparable gallium-68 dotatate and indium-111 pentetreotide scans; management impact was assessed in that subset.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Deppen and colleagues | 97 enrolled patients with known or suspected pulmonary or gastroenteropancreatic neuroendocrine tumors | Prospective imaging study with 78 patients in the scan comparison | Gallium-68 dotatate PET/CT and indium-111 pentetreotide imaging | Gallium-68 PET/CT combined with CT or liver MRI changed care in 28 of 78 patients. No study-related adverse event required treatment. | Management impact came from the subset with comparative scans. The study was not randomized, not all sites were confirmed by biopsy, and a survival benefit from imaging was not established. | Prospective imaging, selected comparison subset |
Cautions
Safety and unknowns
- The injection contributes to cumulative radiation exposure. The label advises limiting close contact with infants and pregnant women for the first 12 hours after administration.
- Hypersensitivity, including rash and itching and less frequent angioedema or features of anaphylaxis, has been reported after approval.
- Nausea, vomiting, and pain or burning at the injection site have been reported after approval; their frequency cannot be estimated reliably.
- Radioactive emissions may cause fetal harm. The label advises a lactating patient to pump and discard breast milk for 12 hours after administration.
Product quality
Product identity and quality
NETSPOT is a kit that requires radiolabeling and quality control before use. Radioactivity changes with time and is measured before injection.
Product and isotope
Gallium-68 dotatate for PET and lutetium-177 dotatate for therapy are different preparations.
Qualified handling
Radiopharmaceutical preparation and administration require qualified personnel and radiation precautions.
Mechanism
How it is proposed to work
Dotatate binds somatostatin receptors. Gallium-68 emits positrons that produce a detectable PET signal, showing where the tracer accumulates.
Binding is strongest at somatostatin receptor subtype 2. Uptake can occur in normal tissues and is not specific to neuroendocrine tumors.
Details
Technical details
Sources
References
- 1.
FDA. NETSPOT prescribing information
US label for the gallium Ga 68 dotatate PET preparation, including activity, acquisition and safety.
- 2.
PubMed. Safety and efficacy of Ga-68 DOTATATE PET/CT for neuroendocrine tumors
doi:10.2967/jnumed.115.163865 PMID:26769865 NCT01396382
Prospective imaging study with a comparison subset and an assessment of intended treatment plans.
- 3.
FDA. LUTATHERA prescribing information
US label for the distinct Lu-177 dotatate treatment.